EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Important Update ​

On January 26th, 2023, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA) for EVUSHELD to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this revision, EVUSHELD is not currently authorized for use in the U.S. until further notice by the Agency.​

The U.S. Government recommends that facilities and providers with unexpired EVUSHELD retain all product in the event that SARS-CoV-2 variants which are neutralized by EVUSHELD become more prevalent in the U.S. in the future.​

Please refer to the HHS website for expiry extension information.